ABSTRACT
Toll-like receptors are a family of transmembrane receptors responsible for recognition and initiation of a response to invading microbes by the immune system. As part of the innate immune system, Toll-like receptors recognise pathogen-associated molecular patterns, highly conserved components that are essential to microbial function. Some of ten toll-like receptors identified in humans are able to recognise several pathogen-associated molecular patterns.
Subject(s)
Toll-Like Receptors/chemistry , Animals , Autoimmune Diseases/physiopathology , Humans , Infections/physiopathology , Lymphocytes/physiology , Macrophages/physiology , Models, Molecular , Signal Transduction , Toll-Like Receptors/immunology , Toll-Like Receptors/physiologyABSTRACT
The availability of mouse monoclonal antibodies has been integral to the classification of human leukocyte cell surface proteins under the "Cluster of Differentiation" or "CD" nomenclature system. The sequencing of the human genome has identified many more proteins that have characteristics similar to the known leukocyte cell surface proteins, but which have not so far been identified using monoclonal antibodies. One factor that may have limited the generation of monoclonal antibodies to some of these proteins is the high level of sequence conservation between the mouse and human proteins, in particular in the extracellular regions that are recognized by most of the widely used antibodies. An alternative approach is to use a more distant species, such as chickens, for the generation of antibody reagents. Here we compare the extent of amino acid differences in the protein CD molecules expressed by human leukocytes and their mouse and chicken homologs. The analysis confirms that the human proteins are more similar to the mouse homologs than the chicken homologs. The results indicate that chicken antibodies have the potential to be used as an alternative to mouse reagents where human-mouse sequence conservation is high.
Subject(s)
Antibodies, Monoclonal/biosynthesis , Leukocytes/chemistry , Membrane Proteins/analysis , Amino Acid Sequence , Animals , Antigens, CD/analysis , Antigens, CD/isolation & purification , Chickens , Conserved Sequence , Humans , Membrane Proteins/isolation & purification , Mice , Molecular Sequence Data , Sequence Homology, Amino AcidABSTRACT
We have prepared single-chain immunoglobulin Fv fragments from the CD20-specific hybridoma HB13d. One scFv clone demonstrated strong binding to a CD20-derived peptide by ELISA and to CD20-positive cells by flow cytometry, a second had reduced binding, and a third clone did not bind the target antigen. Sequence analysis showed that all three constructs contained shared and unique amino acid changes when compared to the nearest germline match. Molecular modelling of the scFv variants revealed that several of the mutations are located in regions predicted to contact antigen, including a mutation in the heavy chain CDR1 of the strongest binding scFv construct. No similar mutation is present in the highly conserved protein sequences of a number of CD20-specific monoclonal antibodies. BIACORE analysis demonstrated that the mutated scFv had approximately three-fold greater antigen-binding activity than another clone. Competition studies showed that the scFv is able to compete with intact CD20 monoclonal antibody for binding to the target antigen. The improved antigen binding of this scFv will permit the construction of novel CD20-specific reagents for the therapy of lymphomas.
Subject(s)
Antigen-Antibody Reactions/genetics , Antigens, CD20/immunology , Complementarity Determining Regions/genetics , Immunoglobulin Fragments/genetics , Mutation , Amino Acid Sequence , Humans , Hybridomas , Immunoglobulin Fragments/immunology , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Variable Region , Models, MolecularABSTRACT
The identification and quantitation of cell-surface proteins expressed by leukocytes currently use the wide availability of monoclonal antibodies (mAb) in immunohistochemical and flow cytometric assays. Presently, approximately 400 such proteins have been characterized; however, analysis of the completed human genome sequence indicates that it may contain several thousand as-yet unidentified molecules, which may be expressed on the leukocyte cell surface. Recent advances in protein isolation and analysis using mass spectrometry illustrate that it is now feasible to identify the protein composition of a complex sample such as a plasma membrane extract. Such an approach may be useful for the identification of the cell-surface proteins that have not been identified using mAb techniques. Here, we detail the results of an in silico evaluation of the peptides isolated using two methods used to label plasma membrane proteins to determine whether these methods are suitable for the identification of known leukocyte cell-surface proteins by mass spectrometry. The labeling of cell-surface proteins before isolation and characterization is a valuable means of differentiating between plasma membrane and internal membrane proteins The results indicate that although the majority of cell-surface proteins can be identified using either of the approaches, others known to be important diagnostically and/or therapeutically would not be identified using either approach. The implication of this for the use of these techniques in the discovery of new leukocyte cell-surface proteins is discussed.
Subject(s)
Computer Simulation , Leukocytes/chemistry , Membrane Proteins/analysis , Amino Acid Sequence , Antigens, CD/analysis , Antigens, CD/isolation & purification , Databases, Factual , Humans , Mass Spectrometry/methods , Membrane Proteins/isolation & purification , Molecular Sequence Data , Peptide Library , Sequence AlignmentABSTRACT
To develop a therapy for drug-resistant B-lineage acute lymphoblastic leukemia (ALL), we transduced T lymphocytes with anti-CD19 chimeric receptors, consisting of an anti-CD19 single-chain variable domain (reactive with most ALL cases), the hinge and transmembrane domains of CD8alpha, and the signaling domain of CD3zeta. We compared the antileukemic activity mediated by a novel receptor ('anti-CD19-BB-zeta') containing the signaling domain of 4-1BB (CD137; a crucial molecule for T-cell antitumor activity) to that of a receptor lacking costimulatory molecules. Retroviral transduction produced efficient and durable receptor expression in human T cells. Lymphocytes expressing anti-CD19-BB-zeta receptors exerted powerful and specific cytotoxicity against ALL cells, which was superior to that of lymphocytes with receptors lacking 4-1BB. Anti-CD19-BB-zeta lymphocytes were remarkably effective in cocultures with bone marrow mesenchymal cells, and against leukemic cells from patients with drug-resistant ALL: as few as 1% anti-CD19-BB-zeta-transduced T cells eliminated most ALL cells within 5 days. These cells also expanded and produced interleukin-2 in response to ALL cells at much higher rates than those of lymphocytes expressing equivalent receptors lacking 4-1BB. We conclude that anti-CD19 chimeric receptors containing 4-1BB are a powerful new tool for T-cell therapy of B-lineage ALL and other CD19+ B-lymphoid malignancies.
Subject(s)
Burkitt Lymphoma/therapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/therapy , Receptors, Nerve Growth Factor/therapeutic use , Receptors, Tumor Necrosis Factor/therapeutic use , Recombinant Fusion Proteins/pharmacology , Antigens, CD , Antigens, CD19/immunology , Burkitt Lymphoma/pathology , CD3 Complex/chemistry , CD3 Complex/genetics , CD3 Complex/pharmacology , CD8 Antigens/chemistry , CD8 Antigens/genetics , CD8 Antigens/pharmacology , Cell Line, Tumor , Coculture Techniques , Cytotoxicity Tests, Immunologic , Humans , Immunoconjugates/genetics , Immunoconjugates/pharmacology , Immunoglobulin Variable Region/genetics , Immunoglobulin Variable Region/pharmacology , Immunotherapy , Precursor Cell Lymphoblastic Leukemia-Lymphoma/pathology , Protein Structure, Tertiary , Receptors, Nerve Growth Factor/genetics , Receptors, Tumor Necrosis Factor/genetics , Recombinant Fusion Proteins/genetics , T-Lymphocytes/cytology , T-Lymphocytes/immunology , T-Lymphocytes/metabolism , Transduction, Genetic , Tumor Necrosis Factor Receptor Superfamily, Member 9Subject(s)
Antigens, CD20/chemistry , Antigens, CD20/physiology , B-Lymphocytes/immunology , Amino Acid Sequence , Animals , Antibodies, Monoclonal/therapeutic use , Antibodies, Monoclonal, Murine-Derived , Humans , Immunohistochemistry/methods , Mice , Molecular Sequence Data , Rituximab , Sequence Homology, Amino AcidABSTRACT
Cancer patients may make antibodies against antigens on the surface of their malignant cells due either to the expression of unique antigens or to dysregulated responses to self antigens. Patients with B cell malignancy frequently produce autoantibodies and may therefore be a source of immunoglobulin genes for the production of phage display antibody libraries directed against tumour-associated antigens. Patients with autoimmune disease have circulating antibodies against lymphocyte surface antigens, and may also provide a good starting point for the production of a library of lymphocyte-reactive antibody structures. In this study, plasma and serum samples from patients with B cell malignancy or Sjogren's syndrome and from healthy controls were screened for antibodies against the B cell membrane antigens CD20. While the majority of samples showed very low reactivity, some individuals did show significant and reproducible binding to CD20. To identify a good donor for library construction, it would be advisable to screen donors for antibody against the antigens of interest.
Subject(s)
Antigens, CD20/immunology , Autoantibodies/analysis , Leukemia, Lymphocytic, Chronic, B-Cell/immunology , Lymphoma, Non-Hodgkin/immunology , Multiple Myeloma/immunology , Enzyme-Linked Immunosorbent Assay , Humans , Peptide LibraryABSTRACT
The success of recombinant antibody fragments as diagnostic reagents and therapeutic agents depends on the availability of sufficient functional material. We have produced a bacterial expression vector that combines high-level expression driven by a modified Shine-Dalgarno sequence with the periplasmic chaperonin Skp. Using this vector, we are able to obtain higher yields of soluble antibody fragments from cultures without the need for supplementation of the culture medium during expression. The fragments produced in the presence of the Skp show improved antigen binding activity compared to when the chaperonin is absent.
Subject(s)
Chaperonins/genetics , Cloning, Molecular/methods , DNA-Binding Proteins/genetics , Escherichia coli Proteins , Genetic Vectors , Immunoglobulin Fragments/genetics , Molecular Chaperones/genetics , Animals , Antigen-Antibody Reactions , Bacterial Proteins/genetics , Flow Cytometry , Humans , Immunoglobulin Fragments/biosynthesis , Immunoglobulin Fragments/immunology , Lewis X Antigen/immunology , Mice , Promoter Regions, Genetic , Recombinant Fusion Proteins/geneticsABSTRACT
The majority of the human Ig heavy chain (IgH) constant (C) region locus has been cloned and mapped. An exception is the region between C delta and C gamma 3, which is unstable and may be a recombination hot spot. We isolated a pBAC clone (pHuIgH3'delta-gamma 3) that established a 52-kb distance between C delta and C gamma 3. Sequence analysis identified a high number of repeat elements, explaining the instability of the region, and an unusually large accumulation of transcription factor-binding motifs, for both lymphocyte-specific and ubiquitous transcription activators (IKAROS, E47, Oct-1, USF, Myc/Max), and for factors that may repress transcription (Delta EF1, Gfi-1, E4BP4, C/EBP beta). Functional analysis in reporter gene assays revealed the importance of the C delta-C gamma 3 interval in lymphocyte differentiation and identified independent regions capable of either enhancement or silencing of reporter gene expression and interaction with the IgH intron enhancer E mu. In transgenic mice, carrying a construct that links the beta-globin reporter to the novel delta-gamma 3 intron enhancer (E delta-gamma 3), transgene transcription is exclusively found in bone marrow B cells from the early stage when IgH rearrangement is initiated up to the successful completion of H and L locus recombination, resulting in Ab expression. These findings suggest that the C delta-C gamma 3 interval exerts regulatory control on Ig gene activation and expression during early lymphoid development.
Subject(s)
B-Lymphocytes/cytology , B-Lymphocytes/immunology , Enhancer Elements, Genetic/immunology , Epitopes, B-Lymphocyte/genetics , Immunoglobulin Constant Regions/genetics , Immunoglobulin Heavy Chains/genetics , Amino Acid Motifs , Animals , B-Lymphocytes/metabolism , Base Composition , Binding Sites/genetics , Binding Sites/immunology , Cell Differentiation/genetics , Cell Differentiation/immunology , Cell Line , Epitopes, B-Lymphocyte/metabolism , Gene Silencing/immunology , Humans , Immunoglobulin Constant Regions/metabolism , Immunoglobulin Heavy Chains/metabolism , Jurkat Cells , Mice , Mice, Inbred C57BL , Mice, Inbred CBA , Mice, Transgenic , Molecular Sequence Data , Repetitive Sequences, Nucleic Acid , Stem Cells/immunology , Stem Cells/metabolism , Transcription Factors/genetics , Transcription Factors/metabolism , Tumor Cells, CulturedSubject(s)
Receptors, IgG/metabolism , Amino Acid Sequence , Animals , Antibodies, Monoclonal , Hematopoietic System/cytology , Hematopoietic System/immunology , Humans , Mice , Mice, Knockout , Molecular Sequence Data , Phenotype , Protein Isoforms/chemistry , Protein Isoforms/genetics , Protein Isoforms/metabolism , Receptors, IgG/chemistry , Receptors, IgG/genetics , Sequence Homology, Amino Acid , Tissue DistributionABSTRACT
We have used YAC (yeast artificial chromosome) technology to create large translocation regions where the c-myc proto-oncogene is coupled to the core region of the human immunoglobulin heavy chain (IgH) locus (from VH2-5 through to Cdelta). Chimeric mice were obtained from embryonic stem cells carrying a single copy of the 240-kb IgH/c-myc translocation region. B-cell tumorigenesis occurs in the translocus mice, even when the entire Emu intron enhancer region between the joining segments and switch mu is deleted. This demonstrates that as yet unidentified regulatory elements in the IgH locus, independent from the known enhancers, are sufficient to cause B-cell specific activation of c-myc after translocation. The phenotype of tumors from IgH/c-myc YAC transgenic mice with or without Emu (B220+, IgM+/IgD+) is reminiscent of Burkitt's lymphoma. A rapidly expanding abnormal B-cell population is present at birth and accumulates in bone marrow, periphery, and spleen, well before discrete tumor establishment. Molecular analysis identified a clonal origin, with rearrangement of one mouse heavy chain allele retained in tumor cells from different sites, whereas subsequent rearrangements of heavy or light chain loci can be diverse. These mice routinely develop mature B-cell tumors early in life and may provide an invaluable resource of a B-cell lymphoma model.
Subject(s)
Chromosomes, Artificial, Yeast/genetics , Enhancer Elements, Genetic , Immunoglobulin Heavy Chains/metabolism , Introns , Lymphoma, B-Cell/genetics , Proto-Oncogene Proteins c-myc/metabolism , Translocation, Genetic , Age Factors , Animals , Blotting, Northern , Blotting, Southern , Flow Cytometry , Mice , Mice, Inbred BALB C , Models, Genetic , Mutagenesis , Phenotype , Polymerase Chain Reaction , Proto-Oncogene Mas , Tissue Distribution , Transplantation ChimeraABSTRACT
We have produced mice that carry the human Ig heavy (IgH) and both kappa and lambda light chain transloci in a background in which the endogenous IgH and kappa loci have been inactivated. The B lymphocyte population in these translocus mice is restored to about one-third of normal levels, with preferential (3:1) expression of human lambda over human kappa. Human IgM is found in the serum at levels between 50 and 400 microg/ml and is elevated following immunization. This primary human Ab repertoire is sufficient to yield diverse Ag-specific responses as judged by analysis of mAbs. The use of DH and J segments is similar to that seen in human B cells, with an analogous pattern of N nucleotide insertion. Maturation of the response is accompanied by somatic hypermutation, which is particularly effective in the light chain transloci. These mice therefore allow the production of Ag-specific repertoires of both IgM,kappa and IgM,lambda Abs and should prove useful for the production of human mAbs for clinical use.
Subject(s)
Chromosomes, Artificial, Yeast/genetics , Immunoglobulin Heavy Chains/biosynthesis , Immunoglobulin Heavy Chains/genetics , Immunoglobulin kappa-Chains/biosynthesis , Immunoglobulin kappa-Chains/genetics , Immunoglobulin lambda-Chains/biosynthesis , Immunoglobulin lambda-Chains/genetics , Animals , Antibody Diversity/genetics , Base Sequence , Chromosomes, Artificial, Yeast/immunology , Crosses, Genetic , Gene Rearrangement, B-Lymphocyte, Heavy Chain , Gene Rearrangement, B-Lymphocyte, Light Chain , Humans , Hybridomas , Immunoglobulin Heavy Chains/blood , Immunoglobulin M/administration & dosage , Immunoglobulin M/biosynthesis , Immunoglobulin M/blood , Immunoglobulin M/genetics , Immunoglobulin kappa-Chains/blood , Immunoglobulin lambda-Chains/blood , Mice , Mice, Inbred BALB C , Mice, Transgenic , Molecular Sequence Data , Receptors, Antigen, B-Cell/biosynthesis , Receptors, Antigen, B-Cell/blood , Receptors, Antigen, B-Cell/geneticsABSTRACT
Transgenic mice carrying a 380-kb region of the human immunoglobulin (Ig) lambda light (L) chain locus in germline configuration were created. The introduced translocus on a yeast artificial chromosome (YAC) accommodates the most proximal Iglambda variable region (V) gene cluster, including 15 Vlambda genes that contribute to >60% of lambda L chains in humans, all Jlambda-Clambda segments, and the 3' enhancer. HuIglambdaYAC mice were bred with animals in which mouse Igkappa production was silenced by gene targeting. In the kappa-/- background, human Iglambda was expressed by approximately 84% of splenic B cells. A striking result was that human Iglambda was also produced at high levels in mice with normal kappa locus. Analysis of bone marrow cells showed that human Iglambda and mouse Igkappa were expressed at similar levels throughout B cell development, suggesting that the Iglambda translocus and the endogenous kappa locus rearrange independently and with equal efficiency at the same developmental stage. This is further supported by the finding that in hybridomas expressing human Iglambda the endogenous L chain loci were in germline configuration. The presence of somatic hypermutation in the human Vlambda genes indicated that the Iglambda-expressing cells function normally. The finding that human lambda genes can be utilized with similar efficiency in mice and humans implies that L chain expression is critically dependent on the configuration of the locus.
Subject(s)
Gene Expression Regulation/immunology , Immunoglobulin lambda-Chains/immunology , Animals , B-Lymphocytes/immunology , Base Sequence , Bone Marrow Cells/immunology , Chromosomes, Artificial, Yeast/genetics , Flow Cytometry , Humans , Immunoglobulin Variable Region/genetics , Immunoglobulin Variable Region/immunology , Immunoglobulin kappa-Chains/genetics , Immunoglobulin kappa-Chains/immunology , Immunoglobulin lambda-Chains/genetics , Mice , Mice, Transgenic , Molecular Sequence Data , Mutation , Spleen/immunologyABSTRACT
The antibody response in the young infant is limited in several ways; in particular, responses generally are of low affinity and restricted to IgM. This raises the question whether the affinity maturation process, consisting of somatic mutation of immunoglobulin genes coupled with selection of high-affinity variants, is operative in the neonate. Re-arranged V(H)6 genes were amplified by polymerase chain reaction (PCR) from cord blood and from peripheral blood of infants. Heteroduplex analysis detected mutation in only 2/18 cord blood samples, while mutations were seen from about 10 days of age onwards. Cloning and sequencing of mutated neonatal V(H)6 genes showed that mutated sequences contained relatively few mutations (one to three mutations per sequence) compared with published values of about 10 in adult IgM sequences. Selection was not evident in the majority of neonatal samples. Thus mutation can occur in the human neonate, but is minimal and generally not accompanied by selection. The age at which affinity maturation develops effectively is yet to be defined.
Subject(s)
Genes, Immunoglobulin/genetics , Infant, Newborn/immunology , Mutation/immunology , Amino Acid Sequence , Base Sequence , Cloning, Molecular , Fetal Blood , Genes, Immunoglobulin/immunology , Humans , Immunoglobulin Variable Region/genetics , Infant , Molecular Sequence Data , Nucleic Acid Heteroduplexes/immunology , Sequence Analysis, DNAABSTRACT
The B cell specific antigen CD19 is a target for the immunotherapy of B lineage leukaemias and lymphomas. We have engineered a single chain Fv (scFv) fragment from the mouse hybridoma cell line FMC63 which produces monoclonal antibody specific for CD19. The genes encoding the FMC63 heavy and light chain variable regions were amplified from cDNA and a scFv was constructed by splice overlap extension PCR. Analysis of staining of lymphoblastoid cell lines, peripheral blood lymphocytes and tonsil sections demonstrated that the monovalent scFv fragment has the same cellular specificity as the parent hybridoma antibody. Kinetic studies with radiolabelled material showed that the scFv binds target cells with a Ka of 2.3 x 10(-9), compared with 4.2 x 10(-9) for the parent antibody. This CD19 scFv will be used in experimental models to test its therapeutic efficacy and immunogenicity, with a view to application in the diagnosis and treatment of human B cell cancers.
Subject(s)
Antigens, CD19/immunology , Immunoglobulin Fragments/immunology , Immunotherapy , Leukemia, B-Cell/immunology , Lymphoma, B-Cell/immunology , Animals , Base Sequence , DNA, Complementary/genetics , DNA, Complementary/immunology , Humans , Immunoglobulin Fragments/genetics , Immunoglobulin Fragments/therapeutic use , Immunoglobulin Variable Region/genetics , Immunoglobulin Variable Region/immunology , Leukemia, B-Cell/therapy , Lymphoma, B-Cell/therapy , Mice , Molecular Sequence Data , Protein EngineeringABSTRACT
To clarify the phenotype of memory B lymphocytes, we have determined the frequency of somatic hypermutations in purified tonsil B cell populations. Our particular interest was the controversial question of whether any memory B-cells express IgD. Ig heavy chain gene rearrangements that used the nonpolymorphic VH6 gene were amplified by PCR, cloned, and sequenced. All eight sequences obtained from the surface IgD (sIgD)-negative fraction contained point mutations, with frequency of one mutation in every 24 bases of sequence. In contrast, only 4 of 12 sequences obtained from the sIgD-positive fraction contained point mutations, with a mutation frequency of one in 600. This frequency was similar to that found for cord blood B cells (one in 550), a population that does not contain memory B cells. These results indicate that although memory B cells are present in the sIgD-negative fraction, no memory cells can be detected in the sIgD-positive fraction of tonsil B lymphocytes.
Subject(s)
Gene Rearrangement, B-Lymphocyte/genetics , Immunoglobulin D/genetics , Immunoglobulin Heavy Chains/genetics , Immunoglobulin Variable Region/genetics , Mutation/genetics , Amino Acid Sequence , B-Lymphocyte Subsets/immunology , Base Sequence , Cloning, Molecular , DNA/analysis , Flow Cytometry , Humans , Immunoglobulin D/immunology , Immunologic Memory/genetics , Molecular Sequence Data , Palatine Tonsil/cytology , Polymerase Chain ReactionABSTRACT
In order to identify somatic hypermutation of rearranged human immunoglobulin genes, we have examined heteroduplex formation between cloned VH6 genes. In test systems, the presence of five or more point mutations could be detected by examining the formation of heteroduplexes between a known germline VH6 gene and other sequenced genes using polyacrylamide gel electrophoresis. If a mutated sequence was used, then the presence of two or more mutations could be detected. The method was used for rapid screening of VH6-D-JH rearrangements for the presence of point mutations before sequencing, and to distinguish between different highly mutated sequences, allowing clones containing the same rearrangement to be identified indirectly.